ClinicalTrials.gg
Status unknownNCT02393482Updated Feb 4, 2021

Psychological Impact of Amenorrhea in Women With Endometriosis

A Phase 4 interventional study of Estroprogestinic therapy (Etinil-estradiol/levonorgestre) and Gonadotropin-releasing hormone agonist (Leuprorelin acetate) in Amenorrhea, Endometriosis and Quality of Life, sponsored by University of Cagliari. Status unknown at 1 site in Italy. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2021-02-04.

Sponsored by University of Cagliari · Phase 4, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Feb 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The purpose of the study is to evaluate the impact on quality of life, psychological health, sexuality and chronic pain of therapies which determine amenorrhea in symptomatic women with endometriosis, through the administration of self reported questionnaires. Amenorrhea in the first group is caused by balanced assumption of estroprogestins, in the second group is caused by GnRHa-induced hypoestrogenism.

02

Conditions studied

  • Amenorrhea
  • Endometriosis
  • Quality of Life
03

In context

Amenorrhea

80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.

This study's planned enrollment of 50 is close to the median of 54 across 49 interventional studies indexed under Amenorrhea.

Browse Amenorrhea studies →

Lead sponsor

University of Cagliari is the lead sponsor of 85 studies on the registry; 17 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical, echographical or surgical diagnosis of endometriosis

Exclusion criteria

Exclusion Criteria:

  • Comorbidity
  • Psychiatric diseases
  • Refusal or inability to sign
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Balanced estroprogestins

    Women assigned to this arm will assume balanced monophasic estroprogestins (etinil-estradiol 100 mcg/levonorgestrel 20 mcg), one tablet orally daily, for 180 days.

    Drug: Estroprogestinic therapy (Etinil-estradiol/levonorgestre)

  • Active comparator
    GnRHa

    Women assigned to this arm will assume Leuprorelin acetate (3,75 mg/2ml), one intramuscular administration every 28 days. After 45 days of treatment, therapy will be implemented with Tibolone 5 mg, one tablet daily orally, and Calcium carbonate/colecalciferol (500 mg/400 UI), one tablet daily orally. This therapy will be prosecuted for the remaining 135 days of treatment.

    Drug: Gonadotropin-releasing hormone agonist (Leuprorelin acetate) · Drug: Add back therapy 1 (tibolone) · Drug: Add back therapy 2 (calcium carbonate/colecalciferol)

Interventions

06

What researchers measure

Primary outcomes

  1. Quality of life (self reported questionnaires)

    This outcome will be evaluated through self reported questionnaires

    Time frame: 180 days

  2. Sexual health (self reported questionnaires)

    This outcome will be evaluated through self reported questionnaires

    Time frame: 180 days

  3. Psychological impact (self reported questionnaires)

    This outcome will be evaluated through self reported questionnaires

    Time frame: 180 days

07

Study locations

1 site
  • University of Cagliari,Obstetrics and Gynecological Department,
    Monserrato, Cagliari 09042, Italy
08

References and documents

Publications

  • McWilliams LA, Cox BJ, Enns MW. Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. Pain. 2003 Nov;106(1-2):127-33. doi: 10.1016/s0304-3959(03)00301-4. PubMed 14581119 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2021; primary completion for Dec 2021, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2015
First posted
Mar 19, 2015
StartEst.
Jun 2021
Primary completionEst.
Dec 2021
CompletionEst.
Jun 2022
Last update
Feb 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02393482
Lead sponsor
University of Cagliari
Responsible party
Stefano Angioni (MD,PhD, University of Cagliari) — Principal investigator
First posted
Mar 19, 2015
Start date
Jun 2021 (estimated)
Primary completion
Dec 2021 (estimated)
Completion
Jun 2022 (estimated)
Last update
Feb 4, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gonadotropin-releasing Hormone Analog · Tibolone

Start the discussion